Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

(R,S)-4-Phosphonophenylglycine, a Potent and Selective Group III Metabotropic Glutamate Receptor Agonist, Is Anticonvulsive and Neuroprotective In Vivo

F. Gasparini, V. Bruno, G. Battaglia, S. Lukic, T. Leonhardt, W. Inderbitzin, D. Laurie, B. Sommer, M. A. Varney, S. D. Hess, E. C. Johnson, R. Kuhn, S. Urwyler, D. Sauer, C. Portet, M. Schmutz, F. Nicoletti and P. J. Flor
Journal of Pharmacology and Experimental Therapeutics June 1999, 289 (3) 1678-1687;
F. Gasparini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V. Bruno
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Battaglia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Lukic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Leonhardt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. Inderbitzin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Laurie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Sommer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. A. Varney
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. D. Hess
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. C. Johnson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Kuhn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Urwyler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Sauer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Portet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Schmutz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Nicoletti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. J. Flor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Group III metabotropic glutamate receptors (mGluRs) are thought to modulate neurotoxicity of excitatory amino acids, via mechanisms of presynaptic inhibition, such as regulation of neurotransmitter release. Here, we describe (R,S)-4-phosphonophenylglycine (PPG) as a novel, potent, and selective agonist for group III mGluRs. In recombinant cell lines expressing the human receptors hmGluR4a, hmGluR6, hmGluR7b, or hmGluR8a, EC50 values for (R,S)-PPG of 5.2 ± 0.7 μM, 4.7 ± 0.9 μM, 185 ± 42 μM, and 0.2 ± 0.1 μM, respectively, were measured. The compound showed EC50 and IC50 values of ≥200 μM at group I and II hmGluRs and was inactive at cloned humanN-methyl-d-aspartate, α-amino-3-hydroxy-5-methyl-isoxazole-4-propionate, and kainate receptors (>300 μM). On the other hand, it showed micromolar affinity for a Ca2+/Cl−-dependentl-glutamate binding site in rat brain, similar to other phosphono-substituted amino acids likel-2-amino-4-phosphonobutyrate. In cultured cortical neurons, (R,S)-PPG provided protection against a toxic pulse ofN-methyl-d-aspartate (EC50 = 12 μM), which was reversed by the group III mGluR antagonist (R,S)-α-methylserine-O-phosphate but not by the group II antagonist (2S)-α-ethylglutamate. Moreover, (R,S)-PPG protected againstN-methyl-d-aspartate- and quinolinic acid-induced striatal lesions in rats and was anticonvulsive in the maximal electroshock model in mice. In contrast to the group III mGluR agonists l-2-amino-4-phosphonobutyrate andl-serine-O-phosphate, (R,S)-PPG showed no proconvulsive effects (2200 nmol i.c.v.). These data provide novel in vivo evidence for group III mGluRs as attractive targets for neuroprotective and anticonvulsive therapy. Also, (R,S)-PPG represents an attractive tool to analyze the roles of group III mGluRs in nervous system physiology and pathology.

Footnotes

  • Send reprint requests to: Dr. Peter J. Flor, K-125.6.08, Nervous System Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. E-mail:peter-josef.flor{at}pharma.novartis.com

  • Abbreviations:
    (1S,3R)-ACPD
    1-aminocyclopentane-1S,3R-dicarboxylic acid
    CHO
    Chinese hamster ovary
    EGlu
    (2S)-α-ethylglutamic acid
    HEK
    human embryonic kidney
    iGluR
    ionotropic glutamate receptor
    l-AP4
    l-2-amino-4-phosphonobutyrate
    mGluR
    metabotropic glutamate receptor
    MSOP
    (R,S)-α-methylserine-O-phosphate
    PCR
    polymerase chain reaction
    PPG
    4-phosphonophenylglycine
    MES
    maximal electroshock test
    GAD
    glutamate decarboxylase
    NMDA
    N-methyl-d-aspartic acid
    GABA
    γ-aminobutyric acid
    • Received October 19, 1998.
    • Accepted January 25, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 289 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 289, Issue 3
1 Jun 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
(R,S)-4-Phosphonophenylglycine, a Potent and Selective Group III Metabotropic Glutamate Receptor Agonist, Is Anticonvulsive and Neuroprotective In Vivo
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

(R,S)-4-Phosphonophenylglycine, a Potent and Selective Group III Metabotropic Glutamate Receptor Agonist, Is Anticonvulsive and Neuroprotective In Vivo

F. Gasparini, V. Bruno, G. Battaglia, S. Lukic, T. Leonhardt, W. Inderbitzin, D. Laurie, B. Sommer, M. A. Varney, S. D. Hess, E. C. Johnson, R. Kuhn, S. Urwyler, D. Sauer, C. Portet, M. Schmutz, F. Nicoletti and P. J. Flor
Journal of Pharmacology and Experimental Therapeutics June 1, 1999, 289 (3) 1678-1687;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

(R,S)-4-Phosphonophenylglycine, a Potent and Selective Group III Metabotropic Glutamate Receptor Agonist, Is Anticonvulsive and Neuroprotective In Vivo

F. Gasparini, V. Bruno, G. Battaglia, S. Lukic, T. Leonhardt, W. Inderbitzin, D. Laurie, B. Sommer, M. A. Varney, S. D. Hess, E. C. Johnson, R. Kuhn, S. Urwyler, D. Sauer, C. Portet, M. Schmutz, F. Nicoletti and P. J. Flor
Journal of Pharmacology and Experimental Therapeutics June 1, 1999, 289 (3) 1678-1687;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PST3093 Stimulates SERCA2a and Improves Cardiac Function
  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Antagonism of Immunostimulatory CpG-Oligodeoxynucleotides by 4-Aminoquinolines and Other Weak Bases: Mechanistic Studies
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics